Anti-Alirocumab-PCSK9 antibody (STJA0032516)
SPECIFICATIONS
ClonalityMonoclonal
HostHumanized
ConjugationUnconjugated
IsotypeIgG1
General Information
| Short Description | Humanized monoclonal anti-Alirocumab-PCSK9 for use in FUNC in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | FUNC |
| Host | Humanized |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Conjugation | Unconjugated |
| Purification | Affinity Purified |
| Formulation | 0.01M PBS, pH 7.2 |
| Storage Instruction | This solution is stable for at least 4 weeks when stored at 2-8°C. For long term storage aseptically aliquot and store at –80°C. Avoid repeated freeze/thaw cycles. |
Target Information
Additional Info
| Background | Alirocumab biosimilar is a human monoclonal antibody (IgG1 isotype) that targets proprotein convertase subtilisin kexin type 9 (PCSK9) , is a PCSK9 inhibitor produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Alirocumab biosimilar consists of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a human kappa light chain. A single Nlinked glycosylation site is located in each heavy chain within the CH2 domain of the Fc constant region of the molecule. The variable domains of the heavy and light chains combine to form the PCSK9 binding site within the antibody. Alirocumab biosimilar has an approximate molecular weight of 146 kDa. |
Information sourced from Uniprot.org